Two Color Single Molecule Sequencing on GenoCare™ 1600 Platform to Facilitate Clinical Applications - Chen, Fang; Liu, Bin; Chen, Meirong; Jiang, Zefei; Zhou, Zhiliang; Wu, Ping; Zhang, Meng; Jin, Huan; Li, Linsen; Lu, Liuyan; Wang, Qi; Shang, Huan; et al. (medRxiv, 2020)
With the rapid development of precision medicine industry, DNA sequencing becomes increasingly important as a research and diagnosis tool. For clinical applications, medical professionals require a platform which is fast, easy to use, and presents clear information relevant to definitive diagnosis. We have developed a single molecule desktop sequencing platform, GenoCare™ 1600. Fast library preparation (without amplification) and simple instrument operation make it friendlier for clinical use. Here we presented sequencing data of E. coli sample from GenoCare™ 1600 with consensus accuracy reaches 99.99%. We also demonstrated sequencing of microbial mixtures and COVID-19 samples from throat swabs. Our data show accurate quantitation of microbial, sensitive identification of SARS-CoV-2 virus and detection of variants confirmed by Sanger sequencing.Competing Interest StatementThe authors declare competing financial interests: all authors are employees or contractors that work for GeneMind Biosciences Company Limited.Funding StatementAll authors are employees of GeneMind Biosciences Company Limited. No external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics Committee of GeneMind Biosciences Company LimitedAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSupplementary material is submitted as "Supplementary Information-Two Color Single Molecule Sequencing on Genocare 1600 Platform to Facilitate Clinical Applications.pdf".